Developing A Class Of Newly Discovered T-cells To Make Cell Therapies More Durable, Longer-lasting and Safer For Patients
RORABio is developing a first-in-class T-cell platform for targeting indications across cancer and infectious diseases. The platform consists of a newly discovered, long-lived, stem-like memory cell population that we call “RORA-Tscm”. Since presence of RORA-Tscm cells correlates with reduced tumor burdens in animal models and is emerging as a hallmark of better clinical outcomes for some patients, we are developing these cells in two formats: 1) modified with a mono- or bispecific chimeric receptor antigen (CAR) to make new CAR-T drugs with potential to be more durable, safer and long-lasting, and 2) as a stand-alone therapy to reconstitute the immune system of HIV infected patients.
RORA-Tscm cells can be scalably expanded to homogeneity under GLP- and GMP-grade like conditions
RORA-Tscm cells are associated with positive clinical outcomes in patients
Flexible T-cell Platform For Making New Cell Therapies
RORA-Tscm cells can be used alone or for making genetically engineered biologics (e.g., expressing a CAR or edited/deleted gene)
February 23, 2023
Case Western Reserve University completes exclusive license agreement with Atlanta-based RORA Biologics Inc. for cancer and HIV therapy technologies
Case Western Reserve University (CWRU) has completed an exclusive license agreement with Atlanta-based RORA Biologics Inc. (RORA-Bio) for intellectual property to develop new therapies to treat HIV and certain kinds of cancer.
The agreement gives RORA-Bio exclusive international rights to T-cell memory stem-cell (RORA cells) technologies developed by Rafick Sekaly, formerly a professor at the CWRU School of Medicine, and co-director of the Center for AIDS Research Proteomics and Systems Biology Core.
For more information